Life science compliance specialist Model N (NYSE: MODN) has announced product enhancements relating to the Inflation Reduction Act.
The firm’s research has shown that pharma executives found regulatory compliance, healthcare policy, and the IRA to be the areas of greatest concern.
In light of this, the company said it had made changes that are geared towards “the increasingly complex regulatory environment for global pharma manufacturers.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze